S-Trityl-L-Cysteine

S-Trityl-L-Cysteine

SCHEMBL6891349

N[C@H](CSC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)O

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 19/20 0.85
DNMT1 P26358 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
S-Trityl-L-Cysteine SCHEMBL768203 1.00 KIF11 (0.85) KIF11DNMT1
S-Trityl-L-Cysteine SCHEMBL768202 1.00 KIF11 (0.85) KIF11DNMT1
S-Trityl-L-Cysteine SCHEMBL11190175 0.98 KIF11 (0.82) KIF11DNMT1
S-Trityl-L-Cysteine SCHEMBL11190178 0.98 KIF11 (0.82) KIF11DNMT1
S-Trityl-L-Cysteine SCHEMBL655694 0.98 KIF11 (0.82) KIF11DNMT1
S-Trityl-L-Cysteine SCHEMBL655692 0.98 KIF11 (0.82) KIF11DNMT1
SCHEMBL12851543 0.91 KIF11 (1.00) KIF11DNMT1
SCHEMBL14537506 0.89 KIF11 (1.00) KIF11DNMT1
SCHEMBL2838308 0.88 KIF11 (0.68) KIF11DNMT1
SCHEMBL7753308 0.88 KIF11 (0.68) KIF11DNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114478368-B Synthesis method and application of chiral paramagnetic probe Py-D-Cys-DTPA 南开大学 2024-09-20 CN claimed
CN-114716515-A Polypeptide analogue and preparation method and application thereof 深圳深创生物药业有限公司 2022-07-08 CN claimed
CN-114478368-A Synthesis method and application of chiral paramagnetic probe Py-D-Cys-DTPA 南开大学 2022-05-13 CN claimed
CN-114262304-A Synthesis method and application of bioluminescent fluorescein responding to Fe (II) ions 武汉大学中南医院 2022-04-01 CN claimed
EP-4722229-A1 ADAPTOR MOLECULES FOR TARGETED CELL IMMUNOTHERAPIES Universität Zürich (CH) 2026-04-08 EP disclosed
US-20260048157-A1 FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY PURDUE RESEARCH FOUNDATION (US) 2026-02-19 US disclosed
US-12508319-B2 Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof PURDUE RESEARCH FOUNDATION (US) 2025-12-30 US disclosed
US-12485179-B2 Cholecystokinin B receptor targeting for imaging and therapy PURDUE RESEARCH FOUNDATION (US) 2025-12-02 US disclosed
US-12397069-B2 Fibroblast activation protein (FAP)-targeted imaging and therapy PURDUE RESEARCH FOUNDATION (US) 2025-08-26 US disclosed
CN-111225688-B FBSA-based therapy and radiological imaging conjugates targeting carbonic anhydrase-positive cancers 普渡研究基金会 2025-06-17 CN disclosed
EP-3672615-B1 FBSA-BASED THERAPEUTIC AND RADIOIMAGING CONJUGATES TARGETING CARBONIC ANHYDRASE POSITIVE CANCERS PURDUE RESEARCH FOUNDATION (US) 2025-04-02 EP disclosed
CN-118725026-A Glycopeptide targeting tumor-associated fibroblast activation protein, radionuclide marker and application thereof 中国科学院上海药物研究所 2024-10-01 CN disclosed
US-20140037961-A1 System For Purifying, Producing And Storing Biomolecules ADC BIOTECHNOLOGY LIMITED (GB) 2014-02-06 US disclosed
US-20140037961-A1 System For Purifying, Producing And Storing Biomolecules ADC BIOTECHNOLOGY LIMITED (GB) 2014-02-06 US disclosed
EP-2508524-A2 Indole compound Takeda Pharmaceutical Company Limited (JP) 2012-10-10 EP disclosed
US-20110033878-A1 LUMINESCENT SUBSTRATE FOR LICIFERASE THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) 2011-02-10 US disclosed
US-20110033878-A1 LUMINESCENT SUBSTRATE FOR LICIFERASE THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) 2011-02-10 US disclosed
EP-0906015-A4 LIVER RETENTION CLEARING AGENTS NEORX CORP (US) 2004-05-12 EP disclosed
EP-0906015-A1 LIVER RETENTION CLEARING AGENTS NEORX CORPORATION (US) 1999-04-07 EP disclosed
WO-1997046099-A1 LIVER RETENTION CLEARING AGENTS NEORX CORPORATION (US) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140037961-A1 System For Purifying, Producing And Storing Biomolecules CRHR2, HCRTR2, KDELR2 KIF11 2538/4885DNMT1 2168/4885
US-12508319-B2 Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof LHCGR, GNRHR, SSTR1 KIF11 2418/4885DNMT1 4091/4885
US-12485179-B2 Cholecystokinin B receptor targeting for imaging and therapy CCKBR, CCKAR, GRPR KIF11 978/4885DNMT1 4649/4885
US-20260048157-A1 FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY FAP, FIBP, FGFR1 KIF11 3473/4885DNMT1 4108/4885
US-12397069-B2 Fibroblast activation protein (FAP)-targeted imaging and therapy FAP, FIBP, FRS2 KIF11 2134/4885DNMT1 4229/4885
US-20110033878-A1 LUMINESCENT SUBSTRATE FOR LICIFERASE GLB1, LSS, NANS KIF11 4818/4885DNMT1 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.